Meanwhile, Curis, with their PI3K HDAC, still wasting their time in lymphomas...lol
Not sure what's so funny about that. They're also testing '907 in MM. If the data pans out, not sure why there can't be room for a drug with an entirely differentiated MoA. Anyways, the market agrees with your skepticism at ~$150M market cap. Happy to take the other side of that bet. ; )
Market Data 
Markets 
AI
